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ABSTRACT: As an alternative strategy to ﬁght antibiotic
resistance, two-component systems (TCSs) have emerged as
novel targets. Among TCSs, master virulence regulators that
control the expression of multiple virulence factors are
considered as excellent antivirulence targets. In Staphylococcus
aureus, virulence factor expression is tightly regulated by a few
master regulators, including the SaeRS TCS. In this study, we
used a SaeRS GFP-reporter system to screen natural
compound inhibitors of SaeRS, and identiﬁed xanthoangelol
B 1, a prenylated chalcone from Angelica keiskei as a hit. We
have synthesized 1 and its derivative PM-56 and shown that 1
and PM-56 both had excellent inhibitory potency against the
SaeRS TCS, as demonstrated by various in vitro and in vivo
experiments. As a mode of action, 1 and PM-56 were shown to bind directly to SaeS and inhibit its histidine kinase activity,
which suggests a possibility of a broad spectrum inhibitor of histidine kinases.
■ INTRODUCTION
Antibiotic resistance has arisen as an extremely serious health
problem in all parts of the world. New resistance mechanisms
are emerging and spreading globally, threatening our ability to
treat common infectious diseases. The list of resistant
infections−such as pneumonia, tuberculosis, blood poisoning,
gonorrhea, and foodborne diseases−is growing longer and
sometimes these are impossible to treat as antibiotics become
less eﬀective.1,2 It is estimated that, by 2050, worldwide drug-
resistant infections will claim 10 million deaths annually. One
particularly problematic pathogen is methicillin-resistant
Staphylococcus aureus (MRSA). MRSA is a nosocomial and
communal menace that is resistant to many antibacterial drugs
and antiseptics.3−5 The U.S. Centers for Disease Control and
Prevention recently issued a report to various governments and
organizations outlining the concern about MRSA. This report
referenced the New Drugs for Bad Bugs (ND4BB) project
initiated by the European Union, the United States military,
and the World Health Organization (WHO).6,7 The
Antimicrobial Resistance Global Report on Surveillance
released by the WHO in 2014 outlined a global initiative to
tackle the MRSA superbug and rekindle a campaign for new,
eﬀective, and safe drugs.8−10 Since they suppress bacterial
growth, conventional antibiotics are conﬁned to a limited
lifespan. It is urgent to establish a new path forward for
medicinal chemists to address successfully this problem.
Among many new approaches, the inhibition of virulence
factors has shown promising outcomes. This strategy bypasses
the route of killing pathogens and thereby has the potential to
suppress the development of resistance. Many such concepts
have been tested.11−13 Among these, two-component systems
(TCSs) that control virulence factors have been of particular
interest.14−17 Some TCSs control multiple virulence factors in
pathogens and are thus called master virulence regulators.18
These TCSs are attractive targets for novel antivirulence
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agents. We identiﬁed one such TCS, the SaeRS system of S.
aureus, as an excellent antivirulence target that is less likely to
evolve resistance.19 We developed a GFP reporter system that
can be applied to a high-throughput assay format. Using this
assay, we discovered certain FDA-approved drugs that exert
antivirulence eﬀects on S. aureus.20 In continuing such studies,
we identiﬁed natural compound inhibitors of the SaeRS TCS
by screening plant-derived products21 using the same assay. Of
the identiﬁed natural products that showed promising
inhibitory activity, we chose xanthoangelol B for further
study including the synthesis of complete xanthoangelol B,
fragments, and a derivative, to test for antivirulence activities.
Xanthoangelol B is a prenylated chalcone isolated from
Ashitaba (Angelica keiskei Koidzumi, Apiaceae). The Japanese
herb Ashitaba is a perennial plant found along the Paciﬁc coast
of Japan. Ashitaba is enriched with numerous active
compounds such as coumarins, ﬂavanones, and chalcones.22−25
Xanthoangelol B is relatively scarce among these compounds,
although it is found in all parts of the plant.26 It shows various
therapeutic properties, such as antioxidative activity, anti-
hypertensive activity, anti-inﬂammatory activity, and antiviral
activity.27 However, although its related chalcones, xanthoan-
gelol and 4-hydroxyderricin, were shown to have an
antibacterial activity against Gram-positive bacteria,28 its
antibacterial activity has not been established. Thus, given
our intriguing screening results, we set out for an in-depth
structure−activity study of xanthoangelol B. We were
particularly interested in its eﬀect on the virulence of S. aureus
and its feasibility as an antivirulence agent.
Xanthoangelol B has a modular structure composed of
chalcone and isoprene moieties. It was deemed important to
analyze the biological activity of its fragments to establish any
structure−activity relationships. Thus, we synthesized frag-
ments of xanthoangelol B along with the parent compound and
tested their activities. During the synthesis, we obtained a
derivative of xanthoangelol B (compound PM-56) that had a
comparable activity and tested its activities. Here, we report
these processes and describe the antivirulence activities of the
compounds that we synthesized.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of biologically relevant gerany-
lated ﬂavanones and geranylated chalcones (such as
(±)-prostratol F, (±)-6-geranyl-5,7-dihydroxy-3′,4′-dimethox-
yﬂavanone, xanthoangelol, 3-geranyl-2,3′,4,4′-tetrahydroxy-
chalcone, and (±)-lespeol) has been reported.29−31 With
these precedents, we designed our syntheses using a
retrosynthetic analysis, as outlined in Scheme 1. Xanthoangelol
B 1 can be disconnected to two main fragments: fragment 3
and 4-hydroxybenzaldehyde 2. Fragment 3 can be obtained
from 2′,4′-dihydroxyacetophenone 4, which is commercially
available. There are two ways to synthesize this fragment 3
(Scheme 1). A synthetic route to 1 was also designed to
generate various fragments that could be evaluated for their
biological activity. The fragments shown in Scheme 1 can
provide insight into the structure−activity relationship of 1
that may help to curtail or enhance its activity.
Our synthetic design involved the limited use of protecting
groups (Scheme 2). Our initial approach was to introduce 2,6-
dimethylhepta-1,6-dien-3-ol at the end of the synthesis to
reduce complications arising from the chiral aliphatic hydroxyl
group. The 4′-hydroxyl position of 2′,4′-dihydroxyacetophe-
none was alkylated with allyl bromide that was heated at 220
°C in N,N-diethylaniline for 24 h. This allowed for Claisen
rearrangement, giving a 3,3-sigmatropic-shifted major product
10 with a 76% yield. The minor product was 5-allyl-2,4-
Scheme 3. Alternative Route for the Synthesis of Xanthoangelol B 1a
aNo metal catalysts involved.
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dihydroxy acetophenone. The regioselectivity of Claisen
rearrangement giving a 3-allylated major product is well
documented.32 Compound 10 was then subjected to aldol
condensation by reﬂuxing for 18 h in KF-alumina (40%), a
solid-support catalyst in toluene. Compound 11 was obtained
as the major product, with a yield of approximately 60%. This
yield was slightly lower than that of most aldol condensation
reactions owing to the two 2′,4′-OH groups. A reaction longer
than 18 h resulted in the formation of a nonpolar mixture of
spots observed by TLC analysis. The nature of the solvent also
drastically inﬂuenced the yield of the reaction. 2,6-
Dimethylhepta-1,6-dien-3-ol was introduced later by initially
synthesizing 2,2-dimethyl-3-(3-methylbut-3-en-1-yl)oxirane 8
from citral by subjecting it to decarbonylation via heating at
130 °C in the presence of catalytic amounts of palladium
acetate (10 mol %) in a sealed tube for 24 h. This produced
2,6-dimethylhepta-1,5-diene 12, with a yield of ca. 62%.33
Dimethylhepta-1,5-diene was subjected to selective oxidation
using m-chloroperbenzoic acid (mCPBA) to obtain an epoxide
8 with a 45% yield.34 Compound 8 was then subjected to
cross-oleﬁn metathesis with 11, using a Hoveyda−Grubbs
second-generation catalyst to yield 70% of an E-product 13.35
The epoxide ring was subsequently subjected to selective ring
opening reactions or isomerization using in situ-generated
diethylaluminum 2,2,6,6-tetramethyl-piperidide to yield the
desired product xanthoangelol B 1 at a 69% yield.36
There were a few interesting observations during the
synthesis of 1 (Scheme S1). As an alternative route to
xanthoangelol B, the introduction of 2,6-dimethylhepta-1,6-
dien-3-ol to the 3′-position of 2,4-dihydroxyacetophenone
resulted in decreased reactivity toward condensation reactions.
Use of a solid-support reagent (such as KF-alumina) or use of
highly basic conditions yielded no product or a complex
mixture of products. Heating the reaction in the presence of a
high boiling-point solvent (either in highly basic or acidic
conditions) yielded no desired product. Finally, the use of L-
proline as an organic catalyst37,38 resulted in an aldol addition
product 15. However, this product did not react further (to
elimination) to yield 1 in any of the acidic or basic conditions
attempted. Thus, 15 was subjected to selective epoxide
isomerization, and the resulting compound PM-56 was tested
for antivirulence activities as a derivative of 1.
Synthesized xanthoangelol B 1 was structurally identical to
the natural product, except for the chiral center. Selective
epoxidation and subsequent epoxide ring opening resulted in
an enantiomeric mixture. We speculated that the number of
required steps to synthesize 1 could be reduced by using a
longer chain (i.e., geranyl bromide) and carrying out
subsequent selective epoxidations, which could be reacted
further to yield 1. This would provide us with an additional
fragment for structure−activity tests and allow us to
incorporate the metal-free chemistry. Thus, we devised a
shorter synthetic route (without using metal catalysts) by
minimizing the use of protecting groups. Speciﬁcally, 2,4-
dihydroxy acetophenone was subjected to aldol condensation
to give an intermediate that was reacted with 1,2-epoxy geranyl
bromide. This generated 13, which underwent selective epoxy-
isomerization to give 1 as an enantiomeric mixture (Scheme
3). Then, we attempted an optical resolution of synthesized
compound 1. We chose a method of enantioselective
organocatalyst oxidative kinetic resolution using the 7-Bn-3-
n-Bu-4-oxa-5-azahomoadamantane/trichloroisocyanuric acid
(TCCA) system to yield a resolved 1.39 The 1H and 13C
NMR spectra of the resolved compound 1 were in agreement
with spectra previously reported.21 The mass spectrum showed
a peak at 409.19 corresponding to [M + H]+, consistent with
the calculated mass of the desired product. In a direct
comparison using HPLC, the synthetic and resolved 1 was
shown to elute at exactly the same retention time as the natural
product (Figure S1). The optical rotation for kinetically
resolved 1 was αD = +13.5 (MeOH, c = 0.5). This is consistent
with the data reported for naturally extracted 1,23 which
indicates the authenticity of the kinetically resolved synthetic
xanthoangelol B 1.
Biological Evaluation of Xanthoangelol B, Its Frag-
ments, and Its Derivative. Previously, we constructed a
SaeRS GFP reporter strain based on the S. aureus USA300
isolate and found promising leads among FDA-approved drugs
through a high throughput screening.20 The same SaeRS GFP
reporter strain was constructed for screening a natural product
library in this study. Brieﬂy, as the α-hemolysin promoter
(Phla) is a well-characterized target of theSaeRS TCS, we
generated a minimal Phla, termed Phlam, which contains only
the SaeR binding sites and the −10/−35 promoter sequences
of the hemolysin gene (hla). Phlam was fused to a green
ﬂuorescence protein (gfp) gene instead of hla in the single-
copy integration plasmid pCL55. The resulting plasmid (pCL-
Phlam-gfp) was inserted into S. aureus USA300. Hence, if the
expression of GFP in a sample was lower than the control
sample, it meant that the SaeRS TCS was inhibited. As the
complete inhibition of Phlam requires a complete shutdown of
the SaeRS TCS (such as a deletion of saeS), Phlam will detect
only potent inhibitors of the SaeRS reporter. Xanthoangelol B
1 was one of the hits among the natural products screened with
this method. Thus, we assayed 1, its fragments, and a derivative
(PM-56). The structures of all the assayed compounds and
fragments are presented in Scheme 4 and Scheme S2.
Scheme 4. Derivatives of Xanthoangelol B
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01012
J. Med. Chem. 2018, 61, 10473−10487
10476
Structure−Activity Studies of Xanthoangelol B and
Its Inhibitory Eﬀect on the SaeRS TCS. On initial
screening, 1 and PM-56 showed an excellent inhibitory
activity against SaeRS. These compounds repressed GFP
expression while allowing bacterial growth, making them ideal
antivirulence candidates. In contrast, all of the fragments
(Scheme S2) failed to inhibit the SaeRS TCS, even at 20 μM.
This indicates that the whole structure is needed for the
inhibitory activity. Furthermore, xanthoangelol and xanthoan-
gelol F (Scheme 4) did not show inhibitory activity at 20 μM.
These two analogs are also natural prenylated chalcones
from Ashitaba, but they lack a hydroxyl group in the terminal
isoprene unit. This hydroxyl group appears to be crucial for the
antivirulence activity of this class of compounds. Xanthoange-
lol with an identical structure to that of 1, except for this
hydroxyl group, did not have any activity (although
methoxylation in the central phenol hydroxyl group of
xanthoangelol F may still have an impact). IC50 values against
the SaeRS GFP reporter were measured to be 2.1 μM for 1 and
4.3 μM for PM-56. In these experiments (at up to 8 and 16
μM), 1 and PM-56 did not disrupt bacterial growth (Figure
1A,C). To elaborate the inhibitory eﬀect of both compounds
on the growth of S. aureus, we measured the growth of S.
aureus in the presence of 1 and PM-56 at higher
concentrations up to 20 h. From 16 μM, 1 started showing
growth inhibition, and at 64 μM of 1, the growth of S. aureus
was severely inhibited (Figure S2). However, up to 64 μM of
PM-56, S. aureus still showed comparable growth to the
control (Figure S2). The trends shown at 8 h did not change
up to 20 h. This indicates that the rigidity conferred to the
chalcone structure by the conjugated double bond is not
essential for anti-SaeRS activity but may lead to higher toxicity
(which aﬀects bacterial growth). Together, these data strongly
indicate that the isoprene and chalcone moieties are necessary
in their entirety for the inhibitory activity.
Eﬀects of Inhibitors on Downstream Virulence
Factors. Staphylococcal α-hemolysin, which causes lysis of
erythrocytes, is the target virulence factor of the SaeRS TCS.
Therefore, if the SaeRS TCS is inhibited, the expression of α-
hemolysin should decrease to a certain degree. When 1 and
PM-56 were incubated with erythrocytes in the presence of
methicillin-resistant S. aureus USA300, notable protection from
hemolysis was observed (Figure 2 and Figure S3). At only 4
μM, both compounds showed visible protection. At 8 μM, a
comparable level of protection to that of saeS knockout
mutants (SaeS::Tn551) was observed. The hemolysis activity
of this saeS mutant was reduced to 82.6% in comparison to the
wild type S. aureus. To conﬁrm the relevance of the protection
eﬀect observed with 1 and PM-56 to the SaeRS pathway, we
also tested 1 and PM-56 against the saeS knockout mutant.
This experiment conducted at 8 μM of 1 and 15 μM of PM-56
showed the reduction in hemolysis by 86.9% and 87.4%,
Figure 1. Various concentrations of compounds were used to treat the USA300-Phlam GFP strain, and GFP expression was analyzed at 8 h. (A)
Measurement of bacterial growth in the presence of xanthoangelol B 1; (B) measurement of ﬂuorescence in the presence of xanthoangelol B 1; (C)
measurement of bacterial growth in the presence of PM-56; (D) measurement of ﬂuorescence in the presence of PM-56. All the experiments were
performed in triplicates, and signiﬁcance was compared with control (no treatment) using one-way ANOVA.
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respectively, compared to hemolysis by the wild type (Figure
S4). Although apparent further inhibition appeared to exist, the
diﬀerences were not statistically signiﬁcant, which thus
suggests that the protection against hemolysis by 1 and PM-
56 is highly likely attributed to inhibition of the SaeRS
pathway. The IC50 values of 1 and PM-56 for the inhibition of
erythrocyte hemolysis were then measured to be 4.6 and 4.0
μM, respectively. These values were consistent with the IC50
values of both compounds for the SaeRS TCS GFP reporter.
Therefore, these strongly suggests that the protection of
erythrocytes from hemolysis in the presence of MRSA can be
attributed to inhibition of the SaeRS TCS.
We next analyzed the transcription of virulence genes in the
presence of 1 and PM-56 (Figure 3). We used concentrations
of 8 μM (1) and 10 μM (PM-56), corresponding to an IC90
value for the SaeRS GFP reporter. We observed signiﬁcant
transcriptional suppression of the following genes: α-hemolysin
(hla), aureolysin (aur), γ-hemolysin, and staphylokinase. These
four genes have a direct SaeR binding site in their promoter
regions and are tightly regulated by the SaeRS TCS.40 While it
has been reported that hla is regulated by an accessory gene
regulator (agr) as well as by sarA, a direct connection between
these regulatory systems and the expression of hla remains
under debate.41 Their suppression likely reﬂects the inhibitory
eﬀects of both compounds on the SaeRS TCS. Then, we
analyzed the transcription of a gene encoding Staphylococcal
accessory regulator (SarA). SarA is responsible for the bioﬁlm
formation and not regulated by saeS. Thus, it was considered a
good negative control, and its transcription analyzed post
treatment of xanthoangelol B 1 and PM-56 (Figure S5). As
anticipated, it can be seen that the level of sarA transcription
was not signiﬁcantly aﬀected by the two compounds. These
results imply that 1 and PM-56 indeed inhibited the SaeRS
pathway with speciﬁcity and thus are promising candidates for
future development of antivirulence agents or chemical probes
speciﬁc for the SaeRS two-component system.
Cytotoxicity. In order to explore the potential of
xanthoangelol B 1 and PM-56 as initial leads for further
Figure 2. Percentage hemolysis values were determined after treating samples with compounds 1 and PM-56 after an 8 h incubation. (A)
Compound 1: various concentrations were used to treat human RBCs, and percentage hemolysis values were calculated relative to the control
sample. (B) Compound PM-56: various concentrations were used to treat human RBCs, and percentage hemolysis values were calculated relative
to the control sample. All the experiments were performed in triplicates and the data calculated by one-way ANOVA. CT, positive control;
SaeS::Tn551, saeS knockout.
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translation, we have examined the cytotoxicity of both
compounds on HeLa cells, quantitatively and qualitatively.
First, LDH release assay was performed, in which we have
treated HeLa cells with 1 and PM-56 at various concentrations
(2−128 μM) for 72 h and measured the optical density at 450
nm. It was shown that IC50 values for HeLa cell survivals were
19.70 and 28.94 μM with 1 and PM-56, respectively (Figure
4A,B). These values were 10-fold and 7-fold higher than IC50
values for the GFP-reporter inhibition by 1 and PM-56,
respectively. Hence, the toxicity/eﬃcacy ratio is reasonable for
the initial leads. Next, the live/dead imaging experiment has
been performed. The HeLa cells were seeded in 96-well plates
for 24 h, and after attachment of cells, the culture media
(DMEM, 10% FBS, 1% penicillin/streptomycin) were
changed, followed by treatment with 1 and PM-56 at various
concentrations (from 2 to 64 μM) for 72 h. The HeLa cells
stained with ﬂuorescein diacetate dye (live cell staining, green
color) and propidium iodide dye (dead cell staining, red color)
were observed using the confocal microscopy (Figure 4 C,D).
Confocal images were in accordance with the quantitative
results as mentioned earlier. Both compounds at their IC90
(approximately 8 μM) for the GFP-reporter did not produce
substantially visible toxicity to the HeLa cells, while a
reduction in viability was observed only when the cells were
treated with concentrations higher than IC50 for cytotoxicity.
Cytotoxicity tests demonstrated that 1 and PM-56 indeed had
the promising traits as initial leads.
Validation of the Antivirulence Activity of Com-
pounds 1 and PM-56 Using a Worm Infection Model.
With the encouraging in vitro data, we further validated the
antivirulence activity of 1 and PM-56 in a Galleria mellonella
infection model. G. mellonella worms possess both a humoral
and an innate immune system. The worms provide an
attractive, simple, and easy-to-handle infection model with
few biosafety or ethical issues. The G. mellonella infection
model has previously been used with several human pathogens
to test the in vivo eﬃcacy of antibacterial and antivirulence
drugs.42 Thus, G. mellonella larvae was challenged with 5 × 106
colony forming units (CFUs), a load designed to allow only
20% survival after 72 h. The larvae was post-treated with
various doses of either 1 or PM-56 at 12 h intervals, up to 72 h.
Larvae health indices were strictly followed and recorded. A
dose-dependent protection from virulence by both compounds
(1 and PM-56) was observed in the larvae (Figure 5).
Compared to the vehicle control, 1 and PM-56 generated a
3.5-fold higher survival at doses as low as 2.0 and 2.1 mg/kg,
respectively. Compound 1 showed 90% survival at a dose of
3.1 mg/kg and complete survival at 4.1 mg/kg. PM-56 showed
90% survival at 3.2 mg/kg and complete survival at 4.3 mg/kg.
These survival rates were comparable to or slightly better than
Figure 3. Eﬀects of 1 and PM-56 on the virulence gene expression were analyzed: (A) hla; (B) aureolysin (aur); (C) ϒ-hemolysin; (D)
staphylokinase. 16S rRNA was used as a reference control gene. All the experiments were performed in triplicates and the data compared with no
treatment control and calculated by one-way ANOVA.
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survival rates observed in worms infected with saeS knockout
strains.
Next, we measured bacterial burden in the host worms. As
shown in Figure S4, the inactivation of saeS resulted in a
decline in the bacterial burden in the host worms (up to 1.7
log10 CFU/worm). Treatment with 1 or PM-56 signiﬁcantly
lowered the bacterial burden in worms in a dose-dependent
manner. Compared to the vehicle control, a dose of
approximately 1 mg/kg allowed a sharp decrease in the
bacterial burden. At concentrations of 4.1 and 4.3 mg/kg,
respectively, 1 and PM-56 generated a decline of 1.72 log10
and 1.84 log10 CFU/worm (Figure S6). Both compounds again
showed comparable eﬃcacy to that of saeS knockout. These
results are highly consistent with survival tests. Then, to
evaluate whether the activities of 1 and PM-56 were based on
the saeS-dependent pathway, we have measured the eﬀects of
both compounds on G. mellonella infected with the saeS
knockout mutant under the same conditions as above. G.
mellonella were challenged with 5 × 106 CFU of the wild type
and the saeS knockout S. aureus, which were subsequently
treated with 1 (2.042 mg/kg body weight) or PM-56 (2.131
mg/kg body weight) for every 12 h interval for 72 h. These
concentrations were corresponding to IC90 for the SaeRS GFP
reporter. The survival rates of G. mellonella infected with the
knockout strain treated with 1 and PM-56 were 70% and 90%,
respectively, while they were 20% for the wild type-infected
larvae and 80% for the knockout strain-infected larvae without
compounds (Figure S7A), which showed protection eﬀects
were comparable. Then, we counted CFU from G. mellonella of
each group after a 72 h infection. It was shown that CFU was
signiﬁcantly decreased in the saeS knockout group as compared
to the wild type infection group by up to 74.5%. Compounds 1
and PM-56 treated groups also showed comparable reduction
in CFU by 76.8% and 83.3%, respectively (Figure S7B).
Together, these results suggest that the protection eﬀects
initiated by the saeS knockout were not drastically improved by
the treatment with 1 and PM-56, and subsequently, the
activities of both compounds on G. mellonela were relevant to
Figure 4. Cytotoxicity of xanthoangelol B and PM-56 on HeLa. (A) Xanthoangelol B and (B) PM-56): LDH release assay. HeLa cells were seeded
in 5 × 105 cells and treated with xanthoangelol B 1 and PM-56 from 2 to 128 μM and incubated for 72 h. The LDH release was analyzed at
OD450 nm. All the experiments were performed in three biological replicates, and data are presented as a mean ± SEM. (C) Xanthoangelol B and
(D) PM-56: live/dead cell staining. HeLa cells were seeded 5 × 105 CFU in a 96-well plate and incubated 24 h for attachment. The various
concentrations of 1 and PM-56 (2 to 64 μM) were tested for 72 h. Then, the cells were stained with FDA and PI and imaged under the confocal
microscope. Green, live; red, dead, (i) vehicle control; (ii) 2 μM; (iii) 4 μM; (iv) 8 μM; (v) 16 μM; (vi) 32 μM; (vii) 64 μM. Images are based on
n = 3 independent experiment.
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the saeS-dependent pathway although we cannot rule out an
extra activity of PM-56 as the eﬀects of PM-56 consistently
showed a slight but nonsigniﬁcant improvement over the saeS
knockout.
Overall, the superb protection given by 1 and PM-56 and
the sharp decline in the bacterial burden following their use
allowed us to draw comparisons with saeS knockout experi-
ments. This hinted at a mode of action for these compounds.
Thus, we next tested 1 and PM-56 for their ability to inhibit
the histidine kinase or phosphotransferase activities of SaeS.
Eﬀects of Compounds 1 and PM-56 on the Histidine
Kinase and Phosphotransferase Activities of SaeS. The
sensor histidine kinase (HK) of a bacterial two-component
system represents a promising antibacterial target, as the
catalytic and ATP-binding (CA) domain of the sensor HK is
well conserved across bacterial species. Thus, an inhibitor
binding this domain has the potential to be a broad-spectrum
antibacterial agent.15 Indeed, many eﬀorts have been made to
discover such a class of inhibitors, with some degree of
success.15,43,44 Compounds 1 and PM-56 displayed excellent
SaeRS-related antivirulence activity in vitro and in vivo. These
results were comparable to the eﬀects seen in saeS knockout
studies. Therefore, it was of great interest to determine
whether these compounds inhibited the sensor HK SaeS. We
tested the two compounds against the puriﬁed minimal kinase
domain of SaeS. The minimal kinase domain contains a
dimerization and histidine phosphotransfer (DHp) domain
and a CA domain (amino acid residues 118−351). Measure-
ments were conducted using a radioisotope method with SDS-
PAGE autoradiography. Both compounds clearly inhibited the
autophosphorylation of SaeS (Figure 6), with IC50 values of
220 and 160 μM for 1 and PM-56, respectively. This was
generally consistent with their observed activities comparable
to the saeS knockout. In contrast, when we measured the
inhibition of phosphotransferase (PT) activity using radio-
actively phosphorylated SaeS in the presence of SaeR, no
inhibition was observed (Figure S8). This implies that only the
HK activity (and not the PT activity) of SaeS is relevant to the
inhibitory activity of 1 and PM-56.
To probe a possibility of 1 and PM-56 as broader HK
inhibitors, we also tested both compounds on AgrC, a
component of another master virulence regulator and the
most well characterized TCS in S. aureus.45 Thus, it was shown
that 1 and PM-56 inhibited AgrC with IC50 values of 339 and
140 μM, respectively (Figure 6). PM-56 showed a comparable
activity to that for SaeS, while 1 showed 1.5-fold lower activity
compared to that for SaeS. This extra activity of PM-56 may
explain slightly higher but nonsigniﬁcant improvement in the
protection eﬀect of PM-56 over the saeS knockout.
Furthermore, PM-56 was 1.4-fold higher activity than 1 for
SaeS, while this diﬀerence expanded to 2.4-fold for AgrC.
Thus, this suggests a potential of the xanthoangelol B scaﬀold
for further development of broad-spectrum or speciﬁc inhibitor
of bacterial histidine kinases.
Figure 5. Ability of compounds 1 (A) and PM-56 (B) to protect G.
mellonella from lethal S. aureus infection. Kaplan−Meier survival
curves for G. mellonella challenged with 5 × 106 CFU S. aureus and
treated with compounds 1 and PM-56 at 2 h postinfection. The
compounds were injected every 12 h for 72 h. The experiments were
performed using biological replicate samples (n = 10). ***P < 0.001,
**P < 0.01, and *P < 0.05 by Student’s t-test.
Figure 6. Inhibitory eﬀects of xanthoangelol B 1 and PM-56 on the in
vitro autokinase activities of SaeS and AgrC. Puriﬁed recombinant
minimal kinase domains of SaeS and AgrC (5 μM each) were
incubated at various concentrations (0−1 mM) of 1 (A) or PM-56
(B) for 15 min on ice before addition of ATP to initiate the
autophosphorylation reactions. After SDS-PAGE analysis, total and
32P-labeled proteins were visualized by Coomassie-Brilliant Blue
staining and autoradiography (32P), respectively. Each lane contains
approximately 0.5 μg puriﬁed SaeS or AgrC. The 32P-labeled protein
bands were quantiﬁed by densitometric analysis, and the autokinase
activities were calculated as the percentages of 32P-labeled proteins in
the samples treated with inhibitory chemicals compared to those in
the control samples treated with 10% DMSO. Dose−response curves
were generated by plotting the percent autokinase activity against the
chemical concentration. The experiments were conducted in
duplicate.
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Next, we attempted to measure the direct binding of 1 and
PM-56 with SaeS using the intrinsic ﬂuorescence quenching
assay. Since SaeS contains seven Tyr (and zero Trp) residues,
the Tyr ﬂuorescence at 306 nm was monitored before and after
binding of 1 and PM-56. The reduction of ﬂuorescence upon
ligand binding was expressed as the percent ﬂuorescence
quenching, and the Kd value was calculated by nonlinear
regression ﬁtting (Figure S9). The quenching assay revealed
that 1 and PM-56 bound to SaeS with the Kd values of 40 and
6.8 μM, respectively. These Kd values are smaller than IC50
values. It is not rare that IC50 values are measured to be much
higher than Kd values,
46−48 and the data are clear indication
that both compounds directly bind to SaeS with consistent
trends of stronger interaction of SaeS with PM-56 than with 1.
Since the binding of PM-56 to SaeS was stronger than that
of 1 as revealed in the inhibition and ﬂuorescence quenching
studies, we selected PM-56 for further dissection of the
inhibitor binding to SaeS. To identify the binding of PM-56 to
SaeS, one-dimensional transverse relaxation ﬁltered experiment
with a Carr−Purcell−Meiboom−Gill pulse trains (1D CPMG)
and 1D saturation transfer diﬀerence experiment (1D STD)
were performed in the presence and absence of the minimal
kinase domain of SaeS.49 The 1D CPMG experiment is able to
detect the reduced T2-relaxation time of the PM-56 peaks
caused by the interaction with SaeS, which results in the peak
broadening and decreasing. The STD NMR spectra obtained
with the minimal kinase domain of SaeS were virtually identical
to those with the kinase domain of SaeS fused to maltose
binding protein (MBP-SaeS) (Figure 7 and Figure S10),
indicating that the presence of MBP does not inﬂuence the
binding. Therefore, MBP-SaeS was used for interpretation of
the 1D STD experiment to enhance the eﬃciency of saturation
transfer from the protein to PM-56. The transferred saturation
from the protein to the ligand is ampliﬁed by the binding
exchange process and is eﬃcient for target proteins with large
molecular weight.50 PM-56 clearly displayed the binding
exchange process to SaeS. Simple 1D spectra also showed that
the peaks of PM-56 were speciﬁcally broadened and shifted by
SaeS, as compared to those of free PM-56 (Figure 7A).
Although the SaeS and MBP-SaeS proteins were dialyzed in
the NMR-buﬀer before the NMR experiments, the HEPES
molecule included in the puriﬁed proteins was not completely
removed. Nevertheless, the spectra of the 1D CPMG (Figure
7B) and 1D STD (Figure 5C) clearly show that PM-56
speciﬁcally binds to SaeS, but HEPES did not. Furthermore,
the similar peak intensities between the 1D spectrum (Figure
7A, red spectrum) and the 1D STD spectrum (Figure 7C)
showed putative interactions involving most parts of PM-56.
Hence, the entire molecular structure appears to be needed to
exert a meaningful inhibition, which is consistent with the test
of fragments. The presence of binding exchange process
accompanied by the clear peak broadening of PM-56 indicates
that the binding aﬃnity between SaeS and PM-56 is likely not
too strong (i.e., nanomolar Kd) or too weak (i.e., millimolar
Kd), which is in agreement with inhibition and binding
measurements.
The IC50 values for HK activity were higher than expected
considering the IC50 values for the SaeRS TCS GFP reporter in
intact bacteria cells. Nevertheless, an observation of substan-
tially lower activity for puriﬁed enzymes than enzymes in intact
cells is not rare.51,52 This could be attributed to the diﬀerent
states of puriﬁed target proteins compared to proteins in intact
cells. There are several factors that may aﬀect protein activity
in intact cells, such as the intracellular distribution of
compounds, processing of target proteins, and presence of
interacting proteins.52 In our case, the puriﬁed SaeS comprised
the minimal kinase domain, which contains only the DHp and
CA domains (amino acid residues 118−351). However, native
SaeS is a modular protein containing transmembrane domains,
a linker, and cytoplasmic domains. The presence of the linker
has a signiﬁcant impact on the kinase activity.53 Therefore, it is
possible that integrity of the whole protein structure is crucial
for its kinase activity. This would also aﬀect its binding aﬃnity
to small molecules. Subsequently, the two inhibitors may
appear to exert a lower inhibitory activity on the puriﬁed SaeS
minimal kinase domain. Nevertheless, inhibition of the kinase
activity of SaeS by 1 and PM-56, supported by STD NMR and
the ﬂuorescence quenching assay, is a signiﬁcant indicator of
their mechanism of action.
Figure 7. One-dimensional NMR analysis of the PM-56 binding to
SaeS. (A) One-dimensional spectrum of PM-56 alone is used as a
blank reference (blue). The several peaks of PM-56 are not shown in
the spectrum due to an overlap with the huge water peak (marked
with an asterisk). The presence of 0.1 mM of the minimal kinase
domain of SaeS apparently decreases and broadens the peaks of PM-
56 (red), and the peak shift of aromatic and oleﬁn protons is also
noted (inset). (B) Transverse relaxation ﬁlter using 200 ms CPMG
pulse trains completely eliminated the peaks of PM-56 in the presence
of 0.1 mM of the minimal kinase domain of SaeS (red). However, the
reduction of the PM-56 peaks by the CPMG ﬁlter is not apparent in
the absence of SaeS (blue). (C) Presence of a binding exchange
process between PM-56 and MBP-SaeS is clearly conﬁrmed by 1D
STD experiment. The PM-56 peaks are speciﬁcally identiﬁed in 1D
STD spectrum in the presence of 30 μM MBP-SaeS. Although the
peak spikes of the remaining buﬀer (HEPES) are identiﬁed, their
integrations are zero; slightly diﬀerent peak shapes between on- and
oﬀ-saturation at 0.5 and 30 ppm, respectively, could result in these
peak spikes.
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We cannot rule out possible contributions to inhibition by
other mechanisms, such as SaeS sensing or SaeR binding to the
promoter regions of virulence genes. Although a majority of
the inhibitors of TCSs reported thus far54 have been HK
inhibitors, a few have shown separate activities against the
sensor16 or the response regulator.15 The evaluation of these
possibilities is complicated, particularly for inhibitors of sensing
activity because SaeS does not have a sensing domain and
likely requires an unknown auxiliary protein.53 Nevertheless,
these studies are currently underway and will be reported in
due course. Given that 1 and PM-56 did not suppress bacterial
growth at IC90 (while inhibiting the SaeRS TCS), these
compounds are excellent candidates for speciﬁc action against
the virulence of S. aureus. In light of this, the necessity of the
whole xanthoangelol B molecule for optimal activity is an
interesting ﬁnding. Neither the isoprenyl nor the chalcone unit
alone displayed activity. Moreover, an overlapping fragment
also failed to show activity. Compounds 1 and PM-56 are
modular compounds composed of isoprene and chalcone. This
result therefore deviates slightly from the logic of a fragment-
based approach.55 This demonstrates that great caution is
needed with fragment-based approaches (although these are
still powerful methods of drug development). The major
diﬀerence between 1 and PM-56 is the conversion of the α,β-
unsaturated carbonyl in the chalcone moiety of 1 to the β-
hydroxyl carbonyl in compound PM-56. This subtle change
appears to confer a diﬀerent activity proﬁle. This will be
valuable information in the further development of antivir-
ulence agents. From the perspective of drug development, it
may be beneﬁcial to think about the route of administration. It
was shown that orally administered xanthoangelol, a
structurally related compound, was absorbed and distributed
rapidly in mice in a single dose study,56 which allows
speculation that 1 and PM-56 may behave similarly. However,
in the same study, the absorption eﬃciency of the chalcone
was evaluated to be low,56 potentially indicative of low oral
bioavailability. The authors stated the limitation of a single
dose study and the major diﬀerence between the results of
bioavailability studies in animals and humans for possible
reasons. Hence, this suggests that many aspects need to be
taken into consideration, and it is considered that it is too early
at the current stage to speculate the route of administration.
Regardless, our data provide a strong starting point for further
optimization.
■ CONCLUSION
In conclusion, we found a hit (xanthoangelol B 1) in a
screening with inhibitory activity against the SaeRS TCS of S.
aureus. A prenylated chalcone, xanthoangelol B 1, was
synthesized in the racemic form and then resolved into an
enantiomeric form. Synthesized xanthoangelol B 1 showed
identical spectroscopic and optical properties to those of
xanthoangelol B 1 extracted from a natural source. We also
synthesized PM-56, a derivative of 1 with a hydrated chalcone
double bond. The two compounds displayed similarly good
inhibitory activities against the SaeRS TCS GFP reporter.
They also inhibited the expression of downstream virulence
factors, reducing hemolysis. PM-56 displayed a better
tolerance for bacterial growth, which is desirable for
antivirulence agents. Interestingly, fragments of the two
compounds did not show any inhibitory activity. Thus, these
compounds are required in their entirety for activity.
Compounds 1 and PM-56 displayed excellent survival rates
and low bacterial burdens in the G. mellonella infection model.
These results were comparable to the eﬀect of saeS knockout.
The in vivo data demonstrated a good correlation with the in
vitro data. Indeed, 1 and PM-56 showed substantial inhibition
of the minimal kinase domain of SaeS, although measured IC50
values were higher than expected from the in vitro (bacteria)
and in vivo data. However, the puriﬁed minimal kinase domain
is not likely to have the same kinase activity as the full-length
membrane protein SaeS. This might explain the lower potency
of 1 and PM-56 against the puriﬁed minimal SaeS.
Fluorescence quenching assay and NMR data support the
direct binding of PM-56 with the minimal kinase domain of
SaeS. This study demonstrates that natural products are still a
valuable source of compounds for therapeutic agents. Eﬀorts
toward the partial or total chemical synthesis or modiﬁcation
of natural products can help diversify a candidate’s structure.
With the expertise and insight gained from our synthesis of
xanthoangelol B 1, we are now in a position to further develop
inhibitors of the SaeRS TCS.
■ EXPERIMENTAL SECTION
General Methods. All reactions were carried out under open ﬂask
unless otherwise stated. THF, toluene, diethyl ether, and CH2Cl2 were
procured from Sigma-Aldrich. Reagents were puriﬁed prior to use
unless otherwise stated. Puriﬁcation of reaction products was carried
out by ﬂash chromatography using Fisher silica gel (35−70 mesh).
NMR spectra were recorded on Bruker DPX 400. 1H NMR spectra
were measured at 400 and 500 MHz. 13C NMR spectra were
measured at 126 and 150 MHz using CDCl3, acetone-d6, or DMSO-d6
as a solvent and internal reference. Coupling constants Js are given in
Hz. Multiplicity as follows: s = singlet, d = doublet, t = triplet, q =
quartet, m = multiplet, br = broad signal. Mass spectrometric data
were obtained on a Waters Acquity UPLC and UPC2 LC systems.
Agilent 1260 inﬁnity was used as an HPLC system to analyze and
purify compounds. Synthesized xanthoangelol B 1 and PM-56 were
screened for PAINS chemotypes using two online tools, PATTERNS
(http://zinc15.docking.org/patterns/home) and FAFDrug4 (http://
fafdrugs3.mti.univ-paris-diderot.fr/), and the results were negative or
PASS.
Xanthoangelol B (1). Diethylaluminum 2,2,6,6-tetramethylpiper-
idide (DATMP) was prepared in situ by reacting diethylaluminum
chloride (6.79 mmol) and lithium 2,2,6,6-tetramethyl piperidide (6.79
mL) in dry toluene (10 mL) under argon atmosphere at 0 °C for 1 h.
The DATMP prepared was used immediately.36 To a stirred mixture
of DATMP (4 mmol) and dry toluene (10 mL), a solution of oxirane
13 (1 mmol) in toluene (3 mL) was added dropwise at 0 °C over a
period of 5−10 min. The reaction mixture was stirred at 0 °C until the
starting material was not detected by TLC. The reaction upon
completion was quenched with ice-cold 1 M HCl, and the resulting
organic phase was separated. The aqueous layer was extracted with
diethyl ether (2 × 10 mL). The organic layer was combined, washed
with brine, dried over anhydrous MgSO4, and concentrated in vacuo.
The residue was puriﬁed by column chromatography (4/1 ethyl
acetate/hexane, Rf = 0.4).
36
Yield: 80%, yellow solid. 1H NMR (400 MHz, acetone-d6) δ ppm
1.62 (m, 2H), 1.74 (s, 3 H), 1.88 (s, 3 H), 2.03−2.29 (m, 3 H), 3.47
(br d, J = 6.8 Hz, 2 H), 3.97 (br t, J = 6 Hz, 1 H), 4.72−4.74 (m, 1
H), 4.87 (s, 1 H), 5.32−5.43 (m, 1 H), 6.50 (d, J = 9 Hz, 1 H), 6.93
(d, J = 8.5 Hz, 2 H), 7.73 (d, J = 15 Hz, 1 H), 7.73 (d, J = 8.5 Hz, 2
H), 7.78 (d, J = 9 Hz, 1 H), 7.86 (d, J = 15 Hz, 1 H). 13C NMR (125
MHz, CDCl3) 192.1, 163.8, 161.4, 157.9, 147.4, 143.9, 138.9, 130.5,
129.2, 127.8, 121.4, 118.6, 118.1, 115.9, 114.1, 111.5, 107.7, 75.6,
35.8, 32.9, 29.7, 18.1, 16.4. Chemical Formula: C25H28O5, calculated
mass [M]: 408.19. Observed [M + H]+: 409.19. Data are consistent
with those reported in ref 23.
Kinetic Resolution:39 Xanthoangelol B (1). In a 25 mL round-
bottomed ﬂask, 1 (0.12 mmol), NaHCO3 (0.24 mmol), and 7-Bn-3-n-
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Bu-4-oxa-5-azahomoadamantane (2.4 μmol) were dissolved in
CH2Cl2 (5 mL). After the reaction mixture was cooled to −40 °C,
trichloroisocyanuric acid (TCCA, 0.024 mmol) was added, and the
mixture was stirred at a ﬁxed temperature (−40 °C) for 12 h. The
mixture was diluted with i-PrOH (1 mL) followed by saturated
aqueous NaHCO3 (10 mL) and warmed to room temperature. The
aqueous layer was separated and extracted with CHCl3. The
combined organic layers were dried over MgSO4 and concentrated
under reduced pressure. The residue was puriﬁed by column
chromatography (45/55 ethyl acetate/hexane, Rf = 0.3) to give the
ketone (48%) and the desired chiral product (34%). Spectroscopic
data were identical as above. [α]D
20 = +13.5 (MeOH, c = 0.5).
Geraniolene Oxide (8). A solution of geraniolene (8.85 mmol) in
CHCl3 (30 mL) was cooled and stirred in an ice-bath to which a
solution of 80% mCPBA (9.74 mmol) in ether (5 mL) was added
dropwise over 30 min and stirred further for an additional 30 min.
The reaction mixture was washed with 10% aqueous Na2CO3 (4 × 10
mL) and saturated NaCl (10 mL). The organic layer was dried (anh.
Mg2SO4), and the solvents were removed on a rotary evaporator to
yield a colorless liquid. The crude product was puriﬁed by short path
distillation under vacuum (ca. 1 mmHg) at room temperature to yield
45% of geraniolene oxide
Yield 45%, pale yellow oil: 1H NMR (400 MHz, C6D6): 2.51 (dd, J
= 4.6, 8.0 Hz, 1 H), 2.05 (m, 2 H), 1.76 (m, 1 H), 1.59 (s, 3 H), 1.49
(m, 1 H), 1.08 (s, 3 H), 1.04 (s, 3 H). Data are consistent with those
reported in ref 57.
Allyl Aryl Ether (9). 2,4-Dihydroxy acetophenone (6.57 mmol) was
dissolved in dry acetone (10 mL), and both anhydrous K2CO3 (9.85
mmol) and allyl bromide (7.23 mmol) were added. The mixture was
reﬂuxed and monitored by thin-layer chromatography (TLC). After
completion of the reaction (8 h), the reaction mixture was ﬁltered and
acetone was removed under vacuum. The residue was puriﬁed by ﬂash
chromatography (9/1 ethyl acetate/hexane, Rf = 0.4) on silica gel to
yield the desired ally aryl ether in an average yield of 76%.
1H NMR (400 MHz, CDCl3) δ = 2.57 (s, 3 H), 3.48 (d, J = 6.1 Hz,
2 H), 5.12 (d, J = 10.3 Hz, 1 H), 5.16 (d, J = 17.1 Hz, 1 H), 5.99 (ddt,
J = 17.1 Hz, J = 10.3 Hz, J = 6.1 Hz, 1 H), 6.24 (s, OH, 1 H), 6.41 (d,
J = 8.8 Hz, 1 H), 7.56 (d, J = 8.8 Hz, 1 H), 12.55 (s, OH, 1 H). Data
are consistent with those reported in ref 32.
1-(3-Allyl-2,4-dihydroxyphenyl)ethan-1-one (10). The allyl aryl
ether (9) (10.41 mmol) was dissolved in 20 mL of N,N-diethylaniline
and reﬂuxed at 220 °C overnight. The reaction upon completion was
cooled to room temperature and poured into 50 mL of precooled
hexane. The separated solid was ﬁltered and washed further with an
excess amount of hexane. The product was puriﬁed by column
chromatography (4/6 ethyl acetate/hexane, Rf = 0.5).
Yield 70%, Brown solid. 1H NMR (400 MHz, chloroform-d) δ ppm
2.57 (s, 3 H), 4.58 (dt, J = 5.38, 1.47 Hz, 3 H), 5.13−5.56 (m, 3 H),
5.91−6.23 (m, 1 H), 6.40−6.58 (m, 2 H), 7.65 (d, J = 8.80 Hz, 1 H),
12.74 (s, 1 H). 13C NMR (101 MHz, chloroform-d) δ ppm 26.22,
68.98, 101.69, 108.03, 114.02, 118.39, 132.32, 165.17, 202.58. Data
are consistent with those reported in ref 32.
1-(3-Allyl-2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-
1-one (11). Alumina (3 g, neutral alumina) was mixed with KF (2 g)
in 20 mL of water, and the water was removed at 50−60 °C in a
rotary evaporator. The impregnated alumina was then dried in a
vacuum drying oven at 75 °C for several hours.58 To a solution of 10
(5.2 mmol) and 4-hydroxybenzaldehyde (5.7 mmol) in dry toluene
(10 mL), the prepared KF-alumina 40% (15.6 mmol) was added. The
reaction mixture was reﬂuxed for 18 h until the reaction was
completed. Upon completion of the reaction, KF-alumina was ﬁltered
oﬀ, the ﬁltrate was evaporated, and the crude product was applied to
column chromatography (1/1 ethyl acetate/hexane, Rf = 0.5) to give
60% of the pure product.
Yield 60%, yellow amorphous powder, 1H NMR (acetone-d6, 400
MHz): 3.39 (td, 2 H, J = 1.6, 6.0 Hz), 4.86 (qd, 1 H, J = 1.6, 10.0
Hz), 4.97 (qd, 1 H, J = 1.6, 16.8 Hz), 5.95 (m, 1 H), 6.51 (d, 1 H, J =
8.4 Hz), 6.90 (d, 2 H, J = 8.4 Hz), 7.71 (d, 2 H, J = 8.4 Hz), 7.72 (d, 1
H, J = 16.0 Hz), 7.81 (d, 1 H, J = 16.0 Hz), 7.97 (d, 1 H, J = 8.4 Hz),
8.98 (s, 1 H, OH), 9.31 (s, 1 H, OH), 13.95 (s, 1 H, OH). Data are
consistent with those reported in ref 59.
2,6-Dimethylhepta-1,5-diene (12). A sealed tube was charged with
molecular sieves (4 Å, 15 g), citral (32.84 mmol), and palladium
acetate (10 mol %). The tube was then purged with argon several
times. Under a counter ﬂow of argon, remaining liquid reagents were
added, followed by cyclohexane (10 mL) by syringe. The tube was
tightly closed by screw cap and placed in a preheated oil bath at
required temperature. The reaction mixture was vigorously stirred for
24 h. The reaction mixture was cooled to room temperature and
ﬁltered through Celite. Reaction tube and residue were washed with
ethyl acetate (20 mL). The ﬁltrate was concentrated, and the resulting
deformylated product was puriﬁed via column chromatography using
silica gel (1/99 ethyl acetate/petroleum ether, Rf = 0.7).
Yield 62%, colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.19−5.08
(t, J = 6.4 Hz, 1 H), 4.71 (d, J = 9.3 Hz, 2 H), 2.21−2.09 (m, 2 H),
2.04 (dd, J = 9.1, 6.2 Hz, 2 H), 1.74 (s, 3 H), 1.70 (s, 3 H), 1.63 (s, 3
H). 13C NMR (100 MHz, CDCl3) δ 145.8, 131.5, 124.1, 109.7, 37.8,
26.3, 25.6, 22.7, 22.4, 17.6. Data are consistent with those reported in
ref 60.
1-(3-((E)-5-(3,3-Dimethyloxiran-2-yl)-3-methylpent-2-en-1-yl)-
2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (13).
Method 1. The Hoveyda−Grubbs second generation catalyst (10
mol %) was purged with argon to a mixture of 1-(3-allyl-2,4-
dihydroxyphenyl)ethan-1-one (4.38 mmol) and 2,2-dimethyl-3-(3-
methylbut-3-en-1-yl)oxirane (14.26 mmol) in DCM. The resulting
solution was stirred at 42 °C for 3 h. Removal of the solvent in vacuo
gave crude product, which was puriﬁed using ﬂash chromatography
(1/1 ethyl acetate/hexane, Rf = 0.4).
61 Yield: 70%.
Method 2. To a solution of 17 (7.8 mmol) and 18 (8.58 mmol) in
30 mL of methanol was added KOH (46.8 mmol) at 0 °C. The
reaction was warmed to room temperature and reﬂuxed for 10 h. The
reaction mixture was cooled with the pH adjusted to 6 using 1 N HCl,
and then extracted with ethyl acetate. The organic layer was
evaporated and puriﬁed by column chromatography (1/1 ethyl
acetate/hexane, Rf = 0.4). Yield: 34%.
Dark yellow solid, 1H NMR (400 MHz, acetone-d6) δ ppm 1.11 (d,
J = 11.00 Hz, 5 H), 1.03−1.17 (m, 1 H), 1.37−1.47 (m, 1 H), 1.80 (s,
3 H), 1.98 (s, 1 H), 2.10 (s, 1 H), 3.18 (d, J = 0.73 Hz, 2 H), 3.35−
3.45 (m, 1 H), 4.71−4.76 (m, 2 H), 5.53 (br s, 1 H), 6.36−6.61 (m, 1
H), 6.39 (dd, J = 2.45, 1.22 Hz, 1 H), 6.94−7.00 (m, 1 H), 7.05 (d, J
= 8.80 Hz, 1 H), 7.79−7.82 (m, 4 H), 8.19 (d, J = 8.80 Hz, 1 H).
(E)-1-(3-(5-(3,3-Dimethyloxiran-2-yl)-3-methylpent-2-en-1-yl)-
2,4-dihydroxyphenyl)ethan-1-one (14). The Hoveyda−Grubbs
second generation catalyst (10 mol %) was purged with argon to a
mixture of 1-(3-allyl-2,4-dihydroxyphenyl)ethan-1-one (5.2 mmol)
and 2,2-dimethyl-3-(3-methylbut-3-en-1-yl)oxirane (10.92 mmol) in
DCM. The resulting solution was stirred at 42 °C for 3 h. Removal of
the solvent in vacuo gave the crude product, which was puriﬁed using
ﬂash chromatography (35/75 ethyl acetate/hexane, Rf = 0.5).
61
1H NMR (400 MHz, CDCl3) δ 13.09 (1 H, s), 7.57 (d, J = 9.0 Hz,
1 H), 6.42 (d, J = 9.0 Hz, 1 H), 5.25(t, J = 6.6 Hz, 1 H,), 4.73 (t, J =
6.3 Hz, 1 H), 3.43 (d, J = 6.3 Hz, 2 H), 2.58 (3 H, s), 2.15−2.01 (4 H,
m), 1.80 (3 H, s), 1.65 (3 H, s), 1.57 (3 H, s). 13C NMR (100 MHz,
CDCl3) δ 202.8, 162.7, 161.8, 137.3, 131.4, 130.0, 124.0, 121.3, 114.7,
113.4, 107.6, 39.6, 26.4, 25.9, 25.5, 21.4, 17.5, 16.0. Chemical formula:
C16H24O4, calculated mass [M]: 304.4. Observed [M + H]
+: 305.37
(E)-1-(3-(5-(3,3-Dimethyloxiran-2-yl)-3-methylpent-2-en-1-yl)-
2,4-dihydroxyphenyl)-3-hydroxy-3-(4-hydroxyphenyl)propan-1-
one (15). To a solution of 14(2.34 mmol) and 2 (2.8 mmol) in 20
mL of DMSO, L-proline (0.23 mmol) was added and reaction was
stirred for 8 h. Upon completion of the reaction, the solvent was
evaporated and column chromatography (1/99 methanol/DCM, Rf =
0.5) performed to yield the desired product. Yield: 67%.
1H NMR (400 MHz, acetone-d6) δ 1.10 (s, 3 H), 1.68 (s, 3 H),
1.13 (3 H, s, CH3), 2.08−2.13 (m, 4 H), 3.18 (d, 2 H, J = 8.6 Hz),
4.72 (m, 1 H), 5.52 (m, 1 H, m), 5.69 (m, 1 H), 6.39 (m, 1 H), 6.50
(d, 1 H, J = 6.9 Hz), 6.94 (d, 2 H, J = 6.6 Hz), 7.06 (d, 1 H, d, J =
15.4 Hz), 7.76 (d, 2 H, J = 8.6 Hz), 7.82 (d, 1 H, J = 8.9 Hz), 7.84 (d,
1 H, J = 15.4 Hz), 13.88 (1 H, s, OH). 13C NMR (100 MHz, CDCl3)
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δ 16.29, 17.72, 21.72, 25.68, 26.33, 39.72, 107.90, 113.95, 114.02,
115.60, 118.19, 121.00, 123.68, 127.92, 129.23, 130.54, 132.15,
139.92, 143.93, 157.83, 161.84, 163.85, 192.14 Chemical formula:
C25H28O5, calculated mass [M]: 408.19. Observed [M + H]
+: 409.2
1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(17). To a solution of 60% KOH in ethanol (10 mL), 2,4-dihydroxy
acetophenone (6.57 mmol) was added followed by 4-hydroxy
benzaldehyde (7.23 mmol). The reaction mixture was reﬂuxed for
about 24 h, and upon completion of reaction, the pH of the reaction
was adjusted to 5. The mixture was then extracted with DCM (3 × 10
mL), washed with water, and dried over anhydrous MgSO4 and
evaporated under vacuum to give crude product. The product was
puriﬁed by column chromatography (6/4 ethyl acetate/hexane, Rf =
0.7) to give 80% of the yield.
Yield 80% yellow solid. 1H NMR (400 MHz, acetone-d6) δ 13.6 (s,
1 H), 12.7 (br s, 1 H), 9.9 (br s, 1 H), 8.13 (d, J = 8.8 Hz, 1 H), 7.78
(s, 2 H), 7.75 (d, J = 8.7 Hz, 2 H), 6.94 (d, J = 8.7 Hz, 2 H), 6.46 (dd,
J = 8.8, 2.3 Hz, 1 H), 6.34 (d, J = 2.4 Hz, 1 H). 13C NMR (100 MHz,
DMSO-d6) δ 191.9, 166.7, 165.2, 164.7, 144.2, 133.5, 130.9, 126.7,
117.3, 115.8, 107.8, 102.5. Data are consistent with those reported in
ref 29.
mCPBA Oxidation of Geranyl Bromide (18). Geranyl bromide
(13.35 mmol) was dissolved in 30 mL of chloroform and cooled to 0
°C. mCPBA (14.02 mmol) was added in small portions over 30 min.
The reaction mixture was stirred further for 30 min at 0 °C. After
completion of the reaction, it was extracted ﬁve times with 1 M
NaHCO3. Organic layer was washed with water, brine, dried over
MgSO4, and concentrated to give the crude product, which was used
further without puriﬁcation.
1-(2,4-Dihydroxy-3-(6-hydroxy-3,7-dimethylocta-2,7-dien-1-yl)-
phenyl)-3-hydroxy-3-(4-hydroxyphenyl)propan-1-one (PM-56).
The same procedure of selective isomerization of oxiranes used for
xanthoangelol B (1) was employed on 15. Upon completion of the
reaction, the solvent was evaporated and the product puriﬁed by
column chromatography (5/95, methanol/DCM, Rf = 0.4).
Yield 67%, dark yellow solid. 1H NMR (400 MHz, CDCl3/D2O) δ
ppm 1.52−1.64 (m, 2 H), 1.68 (s, 2 H), 1.78 (s, 3H), 1.81 (s, 3H),
2.90 (m, 2H), 3.51 (br d, 2 H), 4.08 (br t, 1 H), 4.85 (s, 1 H), 4.95 (s,
1 H), 5.24−5.38 (m, 3 H), 6.09 (br s, 1 H), 6.43 (d, J = 9 Hz, 1 H),
6.90 (d, J = 12 Hz, 2 H), 7.59 (d, J = 12 Hz, 2 H), 7.75 (d, J = 9 Hz, 1
H). 13C NMR (100 MHz, acetone-d6) 199.6, 162.2, 161.6, 156.8,
145.8, 138.4, 137.8, 127.2, 122.8, 117.3, 116.8, 116.1, 112.2, 110.8,
108.5, 76.3, 70.6, 51.9, 35.5, 33.9, 21.8, 17.8, 17.4. Chemical formula:
C25H30O6, calculated mass [M]: 426.2. Observed [M + H]
+: 427.2
HPLC Analysis for Purity. Kinetically resolved xanthoangelol B 1
and PM-56 were analyzed for their purity using an HPLC. The used
system was the Agilent Technologies 1260 Inﬁnity system with a C18
Column (Kromasil 100−5-C18, 5 μm, 21.2 × 250 mm). The column
was eluted with 20/80 acetonitrile/water and the elution monitored
with a UV detector at 254 nm. The program was run for 42 min for 1
and 25 min for PM-56. HPLC showed a single peak for each product,
and the purity is judged to be over 95% (Figure S11).
HPLC Analysis. For all other HPLC analyses, the same system was
used under the same condition except the mobile phase (15/85
acetonitrile/water). The program running time was typically 25 min.
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